Scholarlink

Background <p>Cancer therapy related cardiac dysfunction (CTRCD) is a major concern in breast cancer patients, often reducing left ventricular ejection fraction (LVEF) and causing symptomatic heart failure. This study assessed the comparative effectiveness and safety of cardioprotective drugs in preserving LVEF during chemotherapy.</p> Methods <p>Our database search, included Cochrane, PubMed, WOS, and SCOPUS, from inception to May 1st, 2024, to find randomized controlled trials (RCTs) that assessed the effectiveness and safety of cardioprotective drugs in breast cancer patients undergoing chemotherapy. Bayesian network meta-analysis and meta-regression were performed using the BUGSnet package in R studio version 4.4.2, applying a random-effects model, and mean differences (MD) with 95% credible intervals (CrI) were calculated.</p> Results <p>Eighteen RCTs involving 2,223 patients, met the inclusion criteria. Participants had a mean age was 48.78 (SD: 9.7). Spironolactone provided the greatest improvement in LVEF compared to placebo MD: 12.80; 95% CrI: 5.99 to 19.60, with the highest SUCRA value (97.84). Nebivolol ranked second (MD: 7.30; 95% CrI: 0.34 to 14.25; SUCRA: 81.67), while lisinopril + bisoprolol showed modest benefit (MD: 5.25; 95% CrI: -1.57 to 12.06; SUCRA: 69.43). Other agents, including rosuvastatin, bisoprolol, and candesartan, had variable effects with wide CrIs, and carvedilol and metoprolol showed limited efficacy. Model diagnostics confirmed stable convergence, good model fit, and no significant inconsistency across comparisons. Covariate-adjusted effect size from Bayesian network meta-regression identified hypertension prevalence and sample size as significant positive modifiers of treatment effect. Sensitivity analyses using a leave-one-out approach confirmed the robustness of the findings.</p> Conclusion <p>Spironolactone and nebivolol are promising candidates for preserving LVEF in breast cancer patients undergoing cardiotoxic chemotherapy, while metoprolol showed minimal benefit. However, further studies with larger sample sizes and longer follow-up are essential to validate these results and assess long-term clinical outcomes.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pharmacologic prevention of cardiotoxicity in breast cancer: a Bayesian network meta-analysis and meta-regression

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月3日

查看全文
  • Ali Saad Al-shammari,
  • Ahmed Ibrahim,
  • M Rafiqul Islam,
  • Ahmed Sermed Al Sakini,
  • Pakeezah Tabasum,
  • Rubab Zahra,
  • Naiela E. Almansouri,
  • Hadeel Aboueisha,
  • Hiba Hamdar,
  • Uzair Iqbal,
  • Shanmukh Lingamsetty,
  • Yasar Sattar,
  • Mohamed Abuelazm,
  • Mohanad Albayyaa,
  • Abdelrahman Ali,
  • Cezar Iliescu,
  • Haider Al-Taii,
  • Wissam Khalife

摘要

Background

Cancer therapy related cardiac dysfunction (CTRCD) is a major concern in breast cancer patients, often reducing left ventricular ejection fraction (LVEF) and causing symptomatic heart failure. This study assessed the comparative effectiveness and safety of cardioprotective drugs in preserving LVEF during chemotherapy.

Methods

Our database search, included Cochrane, PubMed, WOS, and SCOPUS, from inception to May 1st, 2024, to find randomized controlled trials (RCTs) that assessed the effectiveness and safety of cardioprotective drugs in breast cancer patients undergoing chemotherapy. Bayesian network meta-analysis and meta-regression were performed using the BUGSnet package in R studio version 4.4.2, applying a random-effects model, and mean differences (MD) with 95% credible intervals (CrI) were calculated.

Results

Eighteen RCTs involving 2,223 patients, met the inclusion criteria. Participants had a mean age was 48.78 (SD: 9.7). Spironolactone provided the greatest improvement in LVEF compared to placebo MD: 12.80; 95% CrI: 5.99 to 19.60, with the highest SUCRA value (97.84). Nebivolol ranked second (MD: 7.30; 95% CrI: 0.34 to 14.25; SUCRA: 81.67), while lisinopril + bisoprolol showed modest benefit (MD: 5.25; 95% CrI: -1.57 to 12.06; SUCRA: 69.43). Other agents, including rosuvastatin, bisoprolol, and candesartan, had variable effects with wide CrIs, and carvedilol and metoprolol showed limited efficacy. Model diagnostics confirmed stable convergence, good model fit, and no significant inconsistency across comparisons. Covariate-adjusted effect size from Bayesian network meta-regression identified hypertension prevalence and sample size as significant positive modifiers of treatment effect. Sensitivity analyses using a leave-one-out approach confirmed the robustness of the findings.

Conclusion

Spironolactone and nebivolol are promising candidates for preserving LVEF in breast cancer patients undergoing cardiotoxic chemotherapy, while metoprolol showed minimal benefit. However, further studies with larger sample sizes and longer follow-up are essential to validate these results and assess long-term clinical outcomes.

Graphical Abstract